Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor

Current developments and applications of microfluidic technology toward clinical translation of nanomedicines

“…The dissolution rate of the obtained cefuroxime axetil amorphous nanoparticles (t50 < 5 min; 450 nm) was faster than the corresponding raw drug powders (t50 ≈ 30 min) [100]. The amorphous cefuroxime axetil nanoparticles can be synthesized at high throughput up to 6 L/min in a microporous tube-in-tube reactor [101]. This reactor offers a general and facile pathway for mass production of the nanoparticles.…”

α-Tocopherol nanosuspensions produced using a supercritical assisted process

“…The increase of suspensions PDI can be explained considering that the viscosity of the drug solution increases with the increase of solute concentration, which obstacles the diffusion of the solvent from the solution to the antisolvent, leading to a large particles size and relatively broad particle size distributions (Zhu et al, 2010).…”

Pharmaceutical Development and Regulatory Considerations for Nanoparticles and Nanoparticulate Drug Delivery Systems

“…Greater increase in the rate of drug dissolution and solubility can be achieved if the nanosized drug particles are amorphous in nature . Significant research has been carried out on amorphous nanometer‐sized APIs, demonstrating their potential as a technology platform for poorly water‐soluble drugs . The nanosized API can be incorporated into a variety of dosage forms for different routes of administration to provide one or more of the following benefits:Increased rate of drug dissolution.Increased rate and extent of drug absorption through oral, dermal, ocular, or pulmonary routes.Reduction in required dose, leading possibly to the use of smaller sized dosage form.Reduced food and gastric pH effect on drug bioavailability.Improved dose proportionality of drug bioavailability.Targeted drug delivery for intravenous injection (passive targeting due to size).…”

“…7,8 Significant research has been carried out on amorphous nanometer-sized APIs, demonstrating their potential as a technology platform for poorly water-soluble drugs. [9][10][11][12][13][14][15][16][17][18] The nanosized API can be incorporated into a variety of dosage forms 19 for different routes of administration to provide one or more of the following benefits:…”